Severe Thrombocytopenia Two Weeks Following Immunization with the Janssen Ad26.CoV2.S Vaccine.
Document Type
Article
Publication Date
7-27-2022
Publication Title
Case Reports in Hematology
Abstract
Immune thrombocytopenia (ITP) has been associated with immunizations with various proposed mechanisms, including overactivation of the immune system and production of antibodies against circulating platelets. ITP has also been associated with several viral infections, including HCV, HIV, and most recently, active SARS-CoV-2 infection. Here, we present a case of a 52-year-old male with no past medical history who sought evaluation with his primary care physician for upper and lower extremity ecchymosis of one week duration. Outpatient laboratory studies were notable for severe isolated thrombocytopenia with platelet count of 8 × 10^9/L. Interestingly, he received the Johnson and Johnson COVID-19 vaccine 16 days prior to his presentation. Clinical work up and laboratory investigations led to the diagnosis of ITP.
Volume
2022
First Page
7208401
Last Page
7208401
Recommended Citation
Antonios B, Zimmer M, Herrman E, Berghea R. Severe thrombocytopenia two weeks following immunization with the Janssen Ad26.CoV2.S vaccine. Case Rep Hematol. 2022 Jul 27;2022:7208401. doi: 10.1155/2022/7208401. PMID: 35911081.
DOI
10.1155/2022/7208401
ISSN
2090-6560
PubMed ID
35911081